Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T38529 Target Info
Target Name Prostaglandin E2 receptor EP2 (PTGER2)
Synonyms Prostanoid EP2 receptor; Prostaglandin E2 receptor EP2 subtype; PGE2 receptor EP2 subtype; PGE receptor, EP2 subtype; PGE receptor EP2 subtype; EP2 receptor
Target Type Successful Target
Gene Name PTGER2
Biochemical Class GPCR rhodopsin
UniProt ID
PE2R2_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2012177618
Title Prostaglandin Receptor Ep2 Antagonists, Derivatives, Compositions, and Uses Related Thereto.
Abstract The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
Applicant(s) Emory University
Representative Drug(s) D0S5EF Drug Info KB = 1.8 nM Click to Show More [1]
2 D0O2EN Drug Info KB = 8.8 nM [1]
3 D0NQ6N Drug Info KB = 18 nM [1]
4 D0W2OT Drug Info Ki = 91 nM [1]
5 D01FIM Drug Info N.A. [1]
6 D03IKW Drug Info N.A. [1]
7 D0G6UA Drug Info N.A. [1]
Patent ID WO2008152093
Title Diaminopyrimidines As Modulators of The Ep2 Receptor.
Abstract The present invention relates to diam inopyrimidines of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.
Applicant(s) Bayer Schering Pharma Ag
Representative Drug(s) D01JJN Drug Info N.A. [1]
United States Patent and Trademark Office (USPTO)
Patent ID US02014179750
Title Prostaglandin Receptor Ep2 Antagonists, Derivatives, Compositions, and Uses Related Thereto.
Representative Drug(s) D0S5EF Drug Info KB = 1.8 nM Click to Show More [1]
2 D06FEA Drug Info Ki = 4.9 nM [1]
3 D0O2EN Drug Info KB = 8.8 nM [1]
4 D01ERV Drug Info KB = 9.6 nM [1]
5 D0NQ6N Drug Info KB = 18 nM [1]
6 D06ZEI Drug Info KB = 22 nM [1]
7 D0A2VQ Drug Info N.A. [1]
8 D0D0PF Drug Info N.A. [1]
9 D0H6QG Drug Info N.A. [1]
10 D0HJ1O Drug Info N.A. [1]
11 D0RD5O Drug Info N.A. [1]
12 D0Y8GN Drug Info N.A. [1]
European Patent Office (EPO)
Patent ID EP20082149552
Title Bsp.5,6-Substituted Benzamide-Derivative As Modulators of Ep2 Receptor European Patent.
Representative Drug(s) D0ZT9N Drug Info N.A. [1]
References  Top
REF 1 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.